The taxane limbo: How low can we go?

Journal of the National Cancer Institute

Volumn 100, Issue 11, 2008, Pages 761-763

  Hudis, Clifford ^a,b   Dang, Chau ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PACLITAXEL; TAXANE DERIVATIVE;

ADD ON THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG SENSITIVITY; EDITORIAL; HUMAN; LEUKEMIA; MICROTUBULE ASSEMBLY; MULTIPLE CYCLE TREATMENT; OPTIMAL DRUG DOSE; PATIENT SELECTION; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT DURATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; META-ANALYSIS AS TOPIC; NEOPLASM STAGING; PACLITAXEL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 44949129002     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn155     Document Type: Editorial

References (28)

1. Seidman A, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol. 1995;13:2575-2581.
2. Hudis C, Seidman A, Crown JPA, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:58-65.
3. Gradishar W, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794-7803.
4. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21(6):976-983.
5. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23(16):3686-3696.
6. Campone M, Fumoleau P, Bourbouloux E, Kerbrat P, Roche H. Taxanes in adjuvant breast cancer setting: which standard in Europe? Crit Rev Oncol Hematol. 2005;55(3):167-175.
7. Martin M, Pienkowski T, Mackey J, et al.; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352(22):2302-2313.
8. Roche H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 2006;24(36):5664-5671.
9. De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 26(1):44-53.
10. Hudis C. Testing chemotherapy for breast cancer: timing is everything. J Clin Oncol. 2005;23(24):5434-5436.
11. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of cancer and leukemia group B protocol 9840. J Clin Oncol. 2008;26(10):1642-1649.
12. Verrill M, Lee J, Cameron D, et al. Anglo-Celtic IV: first results of a UK National Cancer Research Network randomised phase 3 pharmacogenetic trial of weekly versus 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2007;25:18S LBA1005.
13. Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005;23(25):5983-5992.
14. Tabernero J, Climent MA, Lluch A, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol. 2004;15(9):1358-1365.
15. Gradishar W, Krasnojon D, Cheporov S, Makhson A, Manikhas G, Hawkins M. A randomized phase 2 study of weekly or every-3-week nabpaclitaxel versus every-3-week docetaxel as first-line therapy in patients with metastatic breast Cancer. Proc SABCS. 2005.
16. Conlin A, Seidman A, Moynahan M, et al. Randomized phase II trial of 3 dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2 negative metastatic breast cancer: an initial interim safety report ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 25(18S):1104.
17. Guise S, Braguer D, Remacle-Bonnet M, Pommier G, Briand C. Tau protein is involved in the apoptotic process induced by anti-microtubule agents on neuroblastoma cells. Apoptosis. 1999;4(1):47-58.
18. Dumontet C, Isaac S, Souquet PJ, et al. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer. 2005;92(2):E25-E30.
19. Pusztai L. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann Oncol. 2007;18(suppl 12):xii15-xii20.
20. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006;295(14):1658-1667.
21. Romond E, Perez E, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684.
22. Piccart-Gebhart M, Procter M, Leyland-Jones B, et al.; for the HERA Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):659-672.
23. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. In: 29th Annual San Antonio Breast Cancer Symposium. San Antonio, CA. 2006. Abstract 52.
24. Forbes JF, Kennedy J, Pienkowski T, et al. BCIRG 007: randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2006;24:(18S):LBA 516.
25. Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007;357(15):1496-1506.
26. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358(16):1663-1671.
27. Martín M, Rodríguez-Lescure A, Ruiz A, et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst. 2008;100(11):805-814.
28. Moore A. Breast-cancer therapy - looking back to the future. N Engl J Med. 2007;357(15):1547-1549.